"Oximes" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds that contain the radical R2C=N.OH derived from condensation of ALDEHYDES or KETONES with HYDROXYLAMINE. Members of this group are CHOLINESTERASE REACTIVATORS.
| Descriptor ID |
D010091
|
| MeSH Number(s) |
D02.092.570.665
|
| Concept/Terms |
Oximes- Oximes
- Hydroxyimino Compounds
- Compounds, Hydroxyimino
|
Below are MeSH descriptors whose meaning is more general than "Oximes".
Below are MeSH descriptors whose meaning is more specific than "Oximes".
This graph shows the total number of publications written about "Oximes" by people in this website by year, and whether "Oximes" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2011 | 1 | 0 | 1 |
| 2017 | 8 | 9 | 17 |
| 2018 | 1 | 9 | 10 |
| 2019 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Oximes" by people in Profiles.
-
Dramatic clinical response to dabrafenib plus trametinib in anaplastic thyroid carcinoma and the challenges faced during the COVID-19 pandemic. Arch Endocrinol Metab. 2021 Nov 01; 65(2):242-247.
-
Pyrexia by COVID-19 in a patient treated with dabrafenib/trametinib therapy. J Dermatol. 2021 Feb; 48(2):e122-e123.
-
Risk of neuropsychiatric disorders in offspring of COVID-19-infected pregnant women and nutritional intervention. Eur Arch Psychiatry Clin Neurosci. 2021 Mar; 271(2):387-389.
-
Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma. Nat Med. 2019 06; 25(6):941-946.
-
Bull Cancer. 2018 Dec; 105 Suppl 1:S59-S67.
-
PI4KIII inhibitor enviroxime impedes the replication of the hepatitis C virus by inhibiting PI3 kinases. J Antimicrob Chemother. 2018 12 01; 73(12):3375-3384.
-
Characterization of cardiovascular clinical events and impact of event adjudication on the treatment effect of darapladib versus placebo in patients with stable coronary heart disease: Insights from the STABILITY trial. Am Heart J. 2019 02; 208:65-73.
-
BRAFi/MEKi in patients with metastatic melanoma: predictive factors of complete response. Future Oncol. 2019 Jan; 15(2):133-139.
-
Dabrafenib-trametinib combination in 'field-practice': an Italian experience. Future Oncol. 2018 Aug; 14(20):2045-2052.
-
BRAF and MEK inhibitor therapy eliminates Nestin-expressing melanoma cells in human tumors. Pigment Cell Melanoma Res. 2018 11; 31(6):708-719.